Featured Research

from universities, journals, and other organizations

Encouraging early results for redesigned Sapien valve

Date:
March 11, 2013
Source:
American College of Cardiology
Summary:
The new Sapien XT aortic valve showed a non-significantly lower rate of death and strokes at 30 days than the original model, and both valves demonstrated notably better short-term outcomes than seen with the Sapien system in PARTNER I, according to the first results from the PARTNER II study.

The new Sapien XT aortic valve showed a non-significantly lower rate of death and strokes at 30 days than the original model, and both valves demonstrated notably better short-term outcomes than seen with the Sapien system in PARTNER I, according to the first results from the PARTNER II study presented today at the American College of Cardiology's 62nd Annual Scientific Session.

Related Articles


PARTNER II is the first randomized clinical trial involving the Sapien XT valve and the only one that compares the new device to the original FDA-approved Sapien design. The redesigned Sapien XT has been commercially available for some time in most other parts of the world except the United States.

Three years ago the first PARTNER trial reported an almost doubled risk of stroke at 30 days for patients in the Sapien transcatheter system group compared with those who had standard open-heart surgery. After that period, the stroke risk leveled off for both groups. The new valve is part of a three-component system -- a metal stent frame, a valve leaflet and a catheter -- and each piece has been materially changed to make the device smaller andthinner. The frame, formerly stainless steel, is now a thinner cobalt chromium alloy and uses less metal overall, allowing the device to be compressed tighter.

"With the new device, we can treat patients who have smaller vessels with less injury and less trauma, and the valve positioning is more precise," said Martin B. Leon, MD, professor of medicine and director of the Center for Interventional Vascular Therapy, Columbia University Medical Center, New York, and co-principal investigator of the PARTNER studies. "Any time you get below 20 French in catheter size, that's significant for patient safety."

PARTNER II's Cohort B compares the original and new Sapien systems in 560 patients with severe aortic stenosis who were very old, with a mean age more than 84 years, and very sick. More than 96 percent were classified with NYHA Class III (moderate) or Class IV (severe) heart failure, and 59 percent were assessed as clinically frail. All patients were deemed unsuitable for standard open-heart surgery.

This non-inferiority study was designed to show that the new Sapien XT is at least as safe and effective as the old device. At 30 days, all-cause deaths were 3.5 percent for Sapien XT and 5.1 percent for the original device.

"These are the lowest 30-day mortality results for transcatheter aortic valve replacement in any study using rigorous clinical trial methodology," Dr. Leon said. "For these inoperable patients, the sickest of thesick, they're surprisingly good."

Stroke rates at 30 days also were low in both groups, at 3.2 percent for Sapien XT and 3 percent for Sapien, and much lower than in PARTNER I.

The composite one-year endpoint is all-cause mortality, disabling stroke and repeated hospitalization for problems related to aortic stenosis. These data will be presented at the conference.

With the new device, the total procedural time was shorter, the frequency of vascular complications waslower and there were far fewer vascular perforations. In the Sapien group, 10 patients required a second valve because of malfunction or mispositioning, compared with only three patients in the Sapien XT group.

"This device is more stable and doesn't move as much as the original device did," Dr. Leon said. "We didn't give up anything in performance to get this lower profile and its benefits."

The study's Cohort A will compare the new Sapien XT with open-heart surgery in intermediate-risk rather than high-risk patients.

Edwards LifeSciences sponsored PARTNER II and provides research support to Columbia University for the study.


Story Source:

The above story is based on materials provided by American College of Cardiology. Note: Materials may be edited for content and length.


Cite This Page:

American College of Cardiology. "Encouraging early results for redesigned Sapien valve." ScienceDaily. ScienceDaily, 11 March 2013. <www.sciencedaily.com/releases/2013/03/130311101756.htm>.
American College of Cardiology. (2013, March 11). Encouraging early results for redesigned Sapien valve. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2013/03/130311101756.htm
American College of Cardiology. "Encouraging early results for redesigned Sapien valve." ScienceDaily. www.sciencedaily.com/releases/2013/03/130311101756.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins